Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2012

01-02-2012 | Review Article

Highlights of the EANM Congress 2011: Birmingham, UK

Authors: Lioe-Fee de Geus-Oei, Imene Zerizer, Christopher Uebleis, Adil AL-Nahhas

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2012

Login to get access

Abstract

The EANM Congress 2011 took place in Birmingham between the 15th and 19th October 2011 under the presidency of Professor Werner Langsteger. The attendance was reassuringly high, in line with other EANM congresses, despite the current ‘Eurozone Crisis’. Participants from 87 countries came along, met old friends and made new ones. They were presented with a massive programme of 1,480 abstracts, symposia, and CME, scientific, plenary and featured sessions. The industry made a substantial contribution to the success of the congress with 109 hardware, software and radiopharmaceutical companies demonstrating the latest technology and innovations in the field. A feature in this year’s congress was the emphasis on the role of the young generation. The highlight lecture was presented and this article was compiled by three young EANM members chosen from the young investigator project of the EANM. They review the most highly rated presentations in clinical and preclinical imaging in oncology, neuroendocrine tumours, cardiology, paediatrics and neurology, and provide an update on radionuclide therapy, physics, instrumentation, innovative tracers and techniques.
Literature
1.
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S. 18F-FLT PET/CT to guide therapy with EGFR antagonists and Bcl-xL inhibitors in non-small cell lung cancer (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP290.
2.
Heusner TA, Treffert J, Geiger B, Herbrik M, Bockisch A, Antoch G. Diagnostic accuracy of virtual 3D FDG-PET/CT bronchoscopy for the detection of lymph node metastases in non small cell lung cancer patients (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP179.
3.
van den Haak-Siepel FJ, van Dalen JA, de Bruin WI, et al. Added value of 3D FDG-PET/CT mapping of lymph nodes during mediastinoscopy (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP178.
4.
Selcuk NA, Uluc BO, Ordu C, Akosman C. The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small-cell lung cancer (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:P418.
5.
Kobe C, Dietlein M, Borchmann P, et al. Assessment of residual bulky tumor using FDG-PET in patients with advanced stages after completion of chemotherapy. Final report of the GHSG HD15 trial (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP359.
6.
Zanoni L, Agostinelli C, Gallamini A, et al. The predictive value of Interim PET and immunohistochemical markers in Hodgkin lymphoma (HL) (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP356.
7.
Chiaravalloti A, Ragano C, Danieli R, et al. Initial staging of Hodgkin’s disease: role of contrast enhanced FDG PET/CT (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:PW083.
8.
Navales Mateu I, Setoain X, Rodríguez S, et al. Agreement between contrast-enhanced and noncontrast-enhanced PET/CT in initial staging of lymphoma patients (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:P491.
9.
Friesen C, Roscher M, Hormann I, et al. Activation of apoptosis pathways and overcoming of radio- and chemoresistance in myeloid leukaemia cells using monoclonal anti-CD33-antibodies radiolabelled with bismuth-213 (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP187.
10.
Friesen C, Roscher M, Hormann I, et al. Alpha-radiation overcomes DNA-PK and ligase IV playing critical roles in radioresistance and deficient caspases activation in cancer cells (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP585.
11.
Roscher M, Hormann I, Moreno J, et al. Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for chemo- and radioresistant non-Hodgkin’s lymphoma cells (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP587.
12.
Schoffelen R, Boerman OC, van der Graaf WTA, et al. Interim report of a phase I study on pretargeted radioimmunotherapy (PT-RIT) in patients with colorectal cancer (CRC) (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:P469.
13.
Barber TW, Duong CP, Leong T, Drummond EGP, Hicks RJ. 18F-FDG PET/CT influences management and provides powerful prognostic stratification in the primary staging of oesophageal cancer (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP497.
14.
Panagiotidis E, Skylakaki M, Rondogianni P, et al. High incidence of peritoneal implants in recurrence of intraabdominal cancer revealed by 18FDG PET/CT in patients with increased tumour markers and negative findings in conventional imaging (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP516.
15.
Nogami M, Ohnishi M, Kohsaki S, et al. Prone 18F-FDG PET/MRI fusion imaging for breast cancer: comparison with prone PET/multiphase contrast-enhanced CT and breast MRI (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP243.
16.
Donker M, Straver ME, Drukker CA, et al. 99mTc-colloid versus iodine-125 seed for occult lesion localisation in breast conserving surgery after neoadjuvant chemotherapy (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP242.
17.
Spanu A, Sanna D, Chessa F, Piras B, Nuvoli S, Madeddu G. The usefulness of 99mTc-tetrofosmin breast scintigraphy with breast-specific gamma-camera (BSGC) in the detection of residual disease following neoadjuvant therapy (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:PW001.
18.
Koolen B, Vrancken Peeters M, Wesseling J, et al. 18F-FDG PET/CT in primary stage II and III breast cancer: which clinical, biological and genetic characteristics may influence primary tumour uptake? (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP513.
19.
Cochet A, Khoury B, Pigeonnat S, et al. Evaluation of tumour blood flow with dynamic 18F-fluorodeoxyglucose positron emission tomography: correlation with microvessel density (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP248.
20.
Iveson PB, Glaser M, Wilson T, et al. Fluorine-18 labelling and biological evaluation of the HER2-binding Affibody molecule ZHER2:2891 (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP451.
21.
Spinapolice EG, Picchio M, Mapelli P, et al. Role of [18F]fluorodeoxyglucose PET/CT in staging and re-staging gestational trophoblastic neoplasia (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP137.
22.
Mueller A, Oltmanns D, Dewi-Wuelfing P, et al. In vivo detection of apoptosis using 18F-labeled bis(cyclen)-zinc complexes (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:P316.
23.
Petersen H, Polusen MH, Bouchelouche K, et al. [18F]-Fluorocholine PET/CT for preoperative lymph node staging of prostate cancer (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP102.
24.
Marzola MC, Chondrogiannis S, Rampin L, et al. 18F-Choline PET/CT in biochemical relapsed prostate cancer: correlation with PSA value and metastatic spread distribution. Experience on 269 patients (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP103.
25.
Vallabhajosula S, Osborne J, Nikolopoulou A, et al. Novel 99mTc-labeled small molecule inhibitors of prostate specific membrane antigen (PSMA): initial experience in healthy volunteers and men with metastatic prostate adenocarcinoma (PCa) (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP528.
26.
Denoyer D, Kirby L, Roselt P, et al. 18F-FPHCys, a new amino acid derivative as a surrogate biomarker of mTOR inhibition (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP435.
27.
Zerdoud S, Deandreis D, Catargi B, et al. Comparison of four strategies of radioiodine ablation: final results of the randomized, prospective ESTIMABL study on 752 low-risk thyroid cancer patients (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP112.
28.
Andralojc K, Brom M, Claessens-Joosten L, et al. Longitudinal imaging of transplanted islets in a rat model with SPECT. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP261.
29.
Brom M, Joosten L, Frielink C, et al. Non-invasive determination of the beta cell mass in rats by SPECT with 111In-DTPA-exendin-3. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP321.
30.
Mikkola K, Ishizu T, Nuutila P. Labelling of pancreatic islets with α2-adrenoceptor, m3 muscarinic receptor and dopamine D2 receptor ligands in rodents. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP351.
31.
Grassetto G, Marzola MC, Chondrogiannis S, et al. 18F-DOPA PET/CT in the evaluation of hereditary paraganglioma-pheochromocytoma syndromes (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP553.
32.
Ramakrishnan NK, Rybczynska AA, Nyakas CJ, et al. MicroPET scans of rodents with spontaneous pituitary tumors, using the sigma ligand 11C-SA4503 (abstract). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP581.
33.
Fani M, Abiraj K, Del Pozzo L, et al. Preclinical side-by-side comparison of somatostatin antagonists versus clinically applied agonists for PET imaging of neuroendocrine tumors: is 64Cu an alternative to 68Ga? Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP324.
34.
Mueller A, Koglin N, Berndt M, et al. Tumor-specific PET imaging using BAY 94-9392 – a novel F-18 labeled L-glutamate derivative. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP434.
35.
Hooshyar Yousefi B, Drzezga A, von Reutern B, et al. [18F]FIBT a newly developed tracer allows high-contrast imaging of β-amyloid in different age groups of an APP/PS1 mouse model of Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP257.
36.
Fuccio C, Nanni C, Martignani C, et al. 11C-HED PET/CT: variation of cardiac adrenergic activity in patients with idiopathic heart failure disease after CRT. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:PW061.
37.
Andersen TB, Jødal L, Boegsted M, et al. A new pediatric GFR prediction model based on cystatin C, creatinine and body cell mass. Part I: accuracy of the estimate – comparison to six previously published models. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OPO479.
38.
Piccardo A, Lopci E, Conte M, et al. Comparison of 18F-DOPA-PET-CT and 123I-MIBG-scintigraphy in stage 3 and 4 neuroblastoma. A pilot study. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP347.
39.
Brouwer OR, Vermeeren L, van der Ploeg I, et al. Lymphoscintigraphy and SPECT/CT in multicentric/multifocal breast cancer: does each tumour have a separate drainage pattern? Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP631.
40.
Traub-Weidinger T, Kölblinger K, Duan H, et al. 99mTc-MIBI SPECT and 11C-methionine PET/CT imaging of patients with persistent primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP181.
41.
Walter MA, Brunner P, Marincek N, Imhof A, Villard L, Romer A, et al. Response, survival and long-term toxicity of [90Yttrium-DOTA]-TOC in metastasized neuroendocrine cancers. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP310.
42.
Ezziddin S, Sabet A, Heinemann F, Yong-hing C, Ahmadzadehfar H, Guhlke S, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with 177Lu-octreotate. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP240.
43.
Baum RP, Kulkarni HR, Schuchardt C, Fellner M, Rösch F. First clinical experience using 177Lu-BPAMD for the treatment of skeletal metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP638.
44.
Maccauro M, Seregni E, Chiesa C, Romito R, Spreafico C, Morosi C, et al. Results of prospective phase II study on trans artery radioembolization (TARE) with 90Y-Therasphere in hepatocellular carcinoma (HCC) with and without portal vein thrombosis (PVT). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP026.
45.
Aloj L, D’ambrosio L, Aurilio M, Morisco A, Giovannoni L, Mennsen HD, et al. Radioimmunotherapy with Tenarad, a I-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in refractory Hodgkin’s lymphoma: preliminary results. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP238.
46.
Habert M, Wargon I, Le Ber I, Funkiewiez A, Hahn-Barma V, Guicart-Gomez E, et al. Hypometabolism may precede clinical symptoms in fronto-temporal dementia: a study in asymptomatic progranulin mutation carriers. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP085.
47.
Camus V, Payoux P, Barre L, Desgranges B, Voisin T, Tauber C, et al. In vivo imaging of amyloid load in Alzheimer disease and MCI with 18F-AV45 (florbetapir). Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP154.
48.
Sabri O, Gertz H, Ischihara K, Tateno A, Drzezga A, Grimmer T, et al. Global phase 2b efficacy and safety trial of florbetaben for beta-amyloid brain positron emission tomography in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP153.
49.
Finnema SJ, Stepanov V, Nakao R, Sromek AW, Zhang TZ, Neumeyer JL, et al. The first PET evaluation of the fluorine-18 labeled dopamine D2/D3 receptors agonist, [18F]MCL-524. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP272.
50.
Van De Giessen E, De Weijer BA, Janssen I, Van De Laar A, Fliers E, Serlie M, et al. Lower striatal dopamine D2/3 receptor availability in obese compared to non-obese subjects. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP467.
51.
Bagni O, D’arienzo M, Salvatori R, Filippi L, Cannas P, D'agostini A, et al. Can 90Y-PET predict the outcome of lesions after SIRT? Biodistribution assessment and preliminary data of voxel based dosimetry. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP023.
52.
Dieudonné A, Garin E, Laffont S, Rolland Y, Lebtahi R, Gardin I. Clinical feasibility of 3D dosimetry using voxel S-values for the treatment of hepatocellular carcinoma with yttrium 90 microspheres. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP135.
53.
Gear JI, Partridge M, Flux G. Patient specific dosimetry analysis and optimisation using polymer gel dosimetry. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:P742.
54.
Sans Merce M, Barth I, Carnicer A, Donadille L, Ferrari P, Fulop M, et al. Extremity exposure in nuclear medicine: outcome of the ORAMED project. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP459.
55.
Chan C, Cai Z, Reilly R. Novel Auger electron radioimmunotherapeutic agent for HER2-positive breast cancer cells composed of trastuzumab and PAMAM dendrimer displaying multiple DTPA chelators for 111In. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:PW059.
56.
Cooper MS, Ma MT, Sunassee K, Paul RL, Shaw KP, Donnelly PS, et al. In search of the perfect bifunctional chelator for 64Cu-labelled antibodies. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP382.
57.
Orlova A, Malmberg J, Hofström C, Abrahmsén L, Bergman T, Sjöberg A, et al. Affibody molecule 111In-DOTA-ZIGF1R:4551, a new potential probe for imaging of IGF-1R expression in malignant tumours. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:OP381.
Metadata
Title
Highlights of the EANM Congress 2011: Birmingham, UK
Authors
Lioe-Fee de Geus-Oei
Imene Zerizer
Christopher Uebleis
Adil AL-Nahhas
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-2043-2

Other articles of this Issue 2/2012

European Journal of Nuclear Medicine and Molecular Imaging 2/2012 Go to the issue

Original Article

Estimation of regional bone metabolism from whole-body 18F-fluoride PET static images

Editorial

Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease

Society Communications

4th Würzburg Summer School of Thyroid Cancer Management

Editorial

Amyloid-β imaging with PET in Alzheimer’s disease: is it feasible with current radiotracers and technologies?

Obituary

In memoriam: Jean-Luc Moretti

Original Article

Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy